Prognostic Impact of Albumin-bilirubin (ALBI) Grade on Non-small Lung Cell Carcinoma: A Propensity-score Matched Analysis

作者：Fumihiko Kinoshita, Takanori Yamashita, Yuka Oku, Keisuke Kosai, Yuki Ono, Sho Wakasu, Naoki Haratake, Gouji Toyokawa, Tomoyoshi Takenaka, Tetsuzo Tagawa, Mototsugu Shimokawa, Naoki Nakashima, Masaki Mori · 发表于：Anticancer Research · 年份：2021 · DOI：10.21873/anticanres.14924 · 被引用次数：28 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Inflammatory Biomarkers in Disease Prognosis、Cholangiocarcinoma and Gallbladder Cancer Studies

BACKGROUND/AIM: Albumin-bilirubin (ALBI) grade is an indicator of liver dysfunction and is useful for predicting postoperative prognosis of hepatocellular carcinomas. However, the significance of ALBI grade in non-small cell lung carcinoma (NSCLC) has not been elucidated. PATIENTS AND METHODS: We analyzed 947 patients with pStage IA-IIIA NSCLC. We divided patients into ALBI grade 1 and grade 2/3 groups. We then analyzed the association of ABLI grade with clinicopathological characteristics and prognosis in NSCLC by using propensity-score matching. RESULTS: ALBI grade 2/3 was significantly associated with older age, male sex, advanced pT status, and histological type. Even after propensity-score matching, ALBI grade 2/3 patients had significantly worse cancer-specific survival (CSS) than ALBI grade 1 patients (5-year CSS: 87.3% versus 92.8%; p=0.0247). In multivariate analysis, ALBI grade 2/3 was an independent predictor of CSS (HR=1.9; 95%CI=1.11-3.11; p=0.0177). CONCLUSION: ALBI grade was an independent prognostic factor in surgically resected NSCLC.